A discrepancy between an elevated ISI score and a patient's subjective minimization is common and can reflect several patterns. First, patients with chronic insomnia often develop tolerance to their impairment over time, normalizing significant sleep difficulties as 'just how I sleep' rather than recognizing them as a disorder warranting treatment. Second, stigma around sleep complaints — particularly in high-performance or stoic individuals — can lead to minimization during verbal report even when self-report questionnaire responses more accurately reflect actual burden. Third, some patients complete the ISI based on worst-week experiences, inflating scores beyond their typical status. Clinician approach: review each item response with the patient ('I see you rated difficulty falling asleep as a 3 — can you tell me more about what that looks like on a typical night?'). This collaborative review often helps patients recognize patterns they had been minimizing and builds engagement with treatment.

Subthreshold insomnia (ISI 8–14) is not merely a 'mild' condition — it is associated with significantly elevated rates of depression, anxiety, cardiovascular disease, and occupational impairment compared to good sleepers, and has a substantial natural history of progression to clinical insomnia. Whether to treat depends on chronicity, trajectory, distress, daytime impact, and comorbidities. Patients with subthreshold scores and significant daytime distress (item 7 score 3–4) or depression comorbidity ([PHQ-9](/tools/phq9) ≥ 5) may benefit from early brief behavioral intervention. For patients with subthreshold scores and minimal distress, watchful waiting with sleep hygiene education and re-screening in 4 to 8 weeks is reasonable. The goal is not to over-medicalize transient sleep difficulties but to prevent progression to clinical-grade insomnia in those at risk.

The ISI and PSQI are both validated insomnia patient-reported outcome measures but differ in several ways. The ISI has 7 items (score 0–28), takes 2 to 5 minutes, and is specifically optimized for measuring insomnia symptom severity and treatment response. The PSQI has 19 items across 7 component scores (global score 0–21), takes 5 to 10 minutes, and assesses a broader range of sleep quality dimensions including sleep efficiency, sleep duration, sleep quality, sleep disturbance, daytime dysfunction, and use of sleep medication. The ISI is preferred when the clinical or research goal is to quantify insomnia severity and track change over time, particularly in CBT-I treatment monitoring. The PSQI is preferred when a broader characterization of sleep quality is desired, such as in general health research or when sleep duration and efficiency are of interest alongside insomnia severity. Both instruments have extensive validation evidence.

ISI scores in patients taking sleep medication reflect current sleep quality on medication rather than underlying insomnia severity off medication. Patients on effective sleep aids may score in the subthreshold range (8–14) even though their underlying insomnia would score in the severe range if the medication were discontinued. When using the ISI for clinical decision-making in patients on sleep medication, document whether scores reflect medicated or unmedicated sleep. For CBT-I treatment planning in patients on sleep medication, baseline ISI scores should be interpreted in the context of medication use, and the treatment goal typically includes both improving ISI scores and successfully tapering the medication. Post-medication-taper ISI reassessment is important to confirm durable improvement.